Skip to content
logo MSD Oncology Clinical Trials
  • Homepage
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Gastric
    • Gynaecologic
    • Haematological
    • Head and Neck
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Oesophageal
    • Paediatric
    • Prostate
    • Solid Tumours
  • About
  • Common Questions
  • For HCPs
  • English (AU)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Study Keyword: Programmed Cell Death 1 Ligand 2

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), and with respect to overall survival (OS), in participants with non-small cell lung cancer.

Study Keyword: Programmed Cell Death 1 Ligand 2

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

March 7, 2022

By Support_Clique

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion

Study of Pembrolizumab in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent

March 7, 2022

By Tyler Kalist

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility
  • Contact Us

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Merck Sharp & Dohme (Australia) Pty Limited. Level 1 - Building A, 26 Talavera Road, Macquarie Park, NSW 2113
AU-NON-00575 – December 2022

Accessibility

Accessibility